The Medicare GLP-1 Bridge is the most consequential change to weight-loss drug coverage in Medicare’s history, and it opens on July 1, 2026. For the first time, eligible beneficiaries can get brand-name GLP-1 medications such as Wegovy and Zepbound for a flat $50 copay — medicines that otherwise run $500 to $1,000 or more per month at the pharmacy counter. As a senior health writer who has watched obesity medicine collide with the federal rule that has barred Medicare from paying for weight-loss drugs since 2003, I want to walk you through exactly who qualifies, what is covered, and the fine print that will trip people up.
Does Medicare cover weight-loss drugs in 2026? Partly — through a temporary demonstration. The Centers for Medicare & Medicaid Services (CMS) created the Bridge as a time-limited pilot, not permanent coverage. It runs from July 1, 2026 through December 31, 2027, and it sits beside — not inside — your regular Part D drug benefit.
Now Live: What Changed on July 1, 2026
The Medicare GLP-1 Bridge officially launched on July 1, 2026, and several details are now confirmed. This is a time-limited demonstration running through December 31, 2027 — not a permanent benefit — so eligible seniors who want to use it should not wait. A new KFF analysis estimates roughly 3.8 million Medicare beneficiaries could qualify.
The confirmed list of eligible medications is now Foundayo, Wegovy (both the injection and the new tablet), and Zepbound (KwikPen), furnished for a weight-management indication only. Critically, the $50 copay is available through the Bridge only when the drug is prescribed for weight management; if you have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, your regular Part D plan may already cover a GLP-1 and you would use that pathway instead.
Two money details matter. First, your doctor must submit a prior authorization to a central processing center confirming you have received counseling on lifestyle changes. Second — and this surprises people — the $50 copays do not count toward your Part D deductible or the $2,100 out-of-pocket cap for 2026. That is a meaningful caveat if you also take expensive covered drugs, so it is worth reviewing your full medication costs with your care team before enrolling. If you manage diabetes, our guides to GLP-1 coverage under Part D and diabetic supplies explain the alternative pathway.
| Program Detail (Confirmed July 2026) | What It Means for You |
|---|---|
| Runs July 1, 2026 – Dec 31, 2027 | Time-limited — enroll while it lasts |
| Eligible drugs: Foundayo, Wegovy, Zepbound | Weight-management prescription only |
| $50 flat monthly copay | Same price regardless of the drug |
| Does NOT count toward $2,100 cap | Watch total drug spending |
| Prior authorization required | Doctor confirms lifestyle counseling |
| ~3.8 million estimated eligible | BMI 27+ with a qualifying condition |
Table of Contents
- What the Medicare GLP-1 Bridge Is
- Who Qualifies: The Clinical Criteria
- Which Drugs Are Covered
- What You Pay — and the Deductible Catch
- How to Get Started
- Frequently Asked Questions
What the Medicare GLP-1 Bridge Is
Since Part D was created, federal law has excluded drugs used solely for weight loss. That is why a senior with obesity could not get Wegovy through Medicare, while a neighbor with type 2 diabetes could get the nearly identical drug Ozempic. The Medicare GLP-1 Bridge is CMS’s workaround: a demonstration program that provides a temporary coverage pathway for GLP-1 drugs prescribed specifically for chronic weight management. CMS runs it through a single central processor that handles prior authorization, claims, and payment to your pharmacy, rather than routing it through each individual Part D plan.
Think of it as a bridge in two senses: it bridges a long-standing coverage gap, and it bridges the period until Congress or CMS decides whether to make GLP-1 weight-loss coverage permanent. Because it is a pilot with an end date of December 31, 2027, it is wise to treat any benefit you receive as temporary and to plan with your prescriber for what happens after.
Who Qualifies: The Clinical Criteria
Two things must be true. First, you must be enrolled in a standalone Part D prescription drug plan (PDP) or a Medicare Advantage plan that includes drug coverage (an MA-PD) for 2026. People with Original Medicare and no drug plan cannot use the Bridge. Second, you must meet one of three weight-and-health thresholds set by CMS.
| Pathway | Body mass index (BMI) | Required condition |
|---|---|---|
| 1 | 35 or higher | None — BMI alone qualifies |
| 2 | 30 or higher | Heart failure, uncontrolled high blood pressure, OR chronic kidney disease |
| 3 | 27 or higher | Pre-diabetes, prior heart attack, prior stroke, OR symptomatic peripheral artery disease |
Notice the logic: the higher your cardiovascular and metabolic risk, the lower the BMI needed to qualify. This mirrors the clinical evidence that GLP-1 drugs reduce heart attacks and strokes in higher-risk patients, not just pounds on a scale. Your prescriber confirms the diagnosis and submits a prior authorization through the central processor — and importantly, those requests cannot be submitted before July 1, 2026.
Which Drugs Are Covered
As the Bridge opens, three brand-name products are eligible when prescribed to reduce excess body weight and keep it off: Wegovy (both the injection and the newer tablet), the KwikPen formulation of Zepbound, and all formulations of Foundayo. These are semaglutide- and tirzepatide-based medicines — the same molecules generating headlines for double-digit weight loss in clinical trials.
The exclusion that confuses everyone
Here is the counterintuitive part. If you have type 2 diabetes, obstructive sleep apnea, or a liver condition called MASH (metabolic dysfunction-associated steatohepatitis), you are not eligible for the Bridge — because GLP-1 drugs for those diagnoses are already covered under your regular Part D benefit. The Bridge exists only for people whose qualifying reason is weight management itself. If you have one of those other diagnoses, talk to your plan about standard Part D coverage instead, which may carry a different (and sometimes lower) copay.
What You Pay — and the Deductible Catch
Eligible beneficiaries pay a flat $50 copay per fill. Against a cash price that can exceed $1,000 a month, that is a dramatic discount. But read this carefully: your $50 copay does not count toward your Part D deductible and does not count toward your annual out-of-pocket maximum. In 2026 that out-of-pocket cap is $2,100, after which most covered drugs cost you nothing. Because Bridge copays sit outside that cap, they will not help you reach catastrophic coverage faster on your other medications. Budget the $50 as a standalone monthly expense.
| Item | Bridge (weight management) | Standard Part D (e.g., diabetes) |
|---|---|---|
| Your cost | Flat $50 copay | Plan tier copay/coinsurance |
| Counts toward $2,100 cap? | No | Yes |
| Prior authorization | Central CMS processor | Your Part D plan |
| Ends | Dec 31, 2027 | Ongoing |
How to Get Started
Start with your prescriber, not a robocall. Beginning July 1, 2026, your doctor writes the prescription, sends it to the pharmacy, and then completes the prior authorization request that the central processor returns. There is no separate enrollment form you fill out yourself. Bring documentation of your BMI and any qualifying conditions to your appointment so your clinician can submit a complete request the first time. If you are weighing whether a GLP-1 is right for you at all, our deeper explainer on GLP-1 drugs for seniors covers benefits, side effects, and who should be cautious.
A word of caution that bears repeating every time a new benefit launches: scammers will exploit it. Medicare will never call you out of the blue to “sign you up” for a GLP-1 card or ask for your Medicare number or bank details. If you get such a call, hang up and report it to the Senior Medicare Patrol at 1-877-808-2468. For the bigger picture of how your drug costs fit together this year, see our guide to the Medicare Part D $2,100 cap and your full Medicare benefits roadmap.
Frequently Asked Questions
Does Original Medicare cover the GLP-1 Bridge?
You must have a Part D drug plan — either a standalone PDP or a Medicare Advantage plan with drug coverage (MA-PD) for 2026. If you have Original Medicare with no drug plan, you cannot access the Bridge. Adding a Part D plan generally happens during open enrollment or a special enrollment period.
Will the $50 copay ever change or end?
The demonstration is scheduled to run only through December 31, 2027. CMS could adjust, extend, or end it. Because it is a pilot, plan with your prescriber for what your options would be if the Bridge closes — including lifestyle support and whether a qualifying medical diagnosis might shift you to standard Part D coverage.
Can I use the Bridge if I already take Ozempic for diabetes?
No. If you have type 2 diabetes, your GLP-1 is already covered under regular Part D, so you are not eligible for the Bridge. The Bridge is only for people whose qualifying reason is chronic weight management without one of the excluded diagnoses (diabetes, sleep apnea, or MASH).
Do I need a specific BMI to qualify?
A BMI of 35 or higher qualifies on its own. A BMI of 30 or higher qualifies if you also have heart failure, uncontrolled hypertension, or chronic kidney disease. A BMI of 27 or higher qualifies if you have pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. Your clinician confirms both the BMI and the condition.
Related Articles You May Find Helpful
- GLP-1 Drugs for Seniors 2026: Medicare Coverage of Ozempic and Wegovy
- Medicare Part D’s $2,100 Drug Cap in 2026: How Seniors Save Thousands
- Medicare Extra Help 2026: Save Up to $5,900 on Drug Costs
- Medicare Prescription Payment Plan 2026: Stop Paying Drug Costs Upfront
- Medicare Part B Premium Hits $202.90 in 2026 — What to Do Now
Sources
- Centers for Medicare & Medicaid Services (CMS) — Medicare GLP-1 Bridge program and provider guidance, 2026.
- Medicare Rights Center — GLP-1 Weight-Loss Drug Demonstration Begins July 2026.
- CMS Newsroom — CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries.
This article is for general education and is not medical advice. GLP-1 medications carry risks and are not right for everyone. Talk with your doctor or pharmacist about your situation. See our medical disclaimer.
